Skip to content
TrialMatch
Sign up
Recruiting

InRAD Observational Study

Create a profile to match View the full record on ClinicalTrials.gov

About this study

The goal of this international observational study is to evaluate long-term disease outcomes and treatment safety in people with Alzheimer's disease (PwAD), by collecting real-world data from routine clinical practice across global clinical centers. The InRAD Registry Observational Study has several aims: * To collect medical information for many years from a large group of people with Alzheimer's disease. This will be used for research, which will support improved understanding about the disease. * To enable researchers to look at the effectiveness, usefulness and safety of treatments for Alzheimer's disease. * To enable researchers to answer similar research questions and compare results in many different areas of the world. People with Alzheimer's disease who meet the eligibility criteria and agree to participate in the Study will be asked to visit their doctor (e.g. psychiatrist, geriatrician, or neurologist) at least once a year, or as frequently as is needed for their care. During or after their appointments they may be offered assessments, tests, medications, and treatments as determined by their doctor and their team. This is an observational data collection.

Condition
Alzheimer's Disease(AD), Mild Cognitive Impairment (MCI), Subjective Cognitive Decline (SCD), Non-Alzheimer Degenerative Dementia
Tested
None, this is a non-interventional observational study
Sponsor
Stichting International Registry for Alzheimer's Disease and other Dementias Foundation

Who can join

Age
18 years and older
Sex
All sexes
Healthy volunteers
Not accepted

Inclusion 6

  • Minimum age: 18 years
  • Study condition: Alzheimer's Disease(AD), Mild Cognitive Impairment (MCI), Subjective Cognitive Decline (SCD), Non-Alzheimer Degenerative Dementia
  • Be undergoing diagnostic work-up for Alzheimer's disease (AD), OR
  • Have a confirmed diagnosis of AD (whether currently treated with an AD-specific treatment, or untreated),
  • Be attending an InRAD Center,
  • Have provided informed consent for long-term follow-up

Exclusion 2

  • Any patient or legal representative who is unable or unwilling to provide a signed informed consent form
  • The protocol does not specify a lower or upper age limit. Participants are expected to be predominantly adults, and can include younger adults with early-onset or genetically determined Alzheimer's disease (e.g. Down syndrome-associated Alzheimer's disease).

Where

22 sites, 22 recruiting

Alfred Hospital

Melbourne, Australia

Recruiting

Medical University of Graz

Graz, Austria

Recruiting

Kardinal Schwarzenberg Klinikum

Schwarzach, Austria

Recruiting

UZLeuven

Leuven, Belgium

Recruiting

Irmandade da Santa Casa de São Paulo

São Paulo, Brazil

Recruiting

Motol and Homolka University Hospital (UHM)

Prague, Czechia

Recruiting

and 16 more sites on ClinicalTrials.gov

Contact

Potential match only. Final eligibility is determined by the study team.